CSIMarket Company Name, Ticker, Suppliers, else..
 
Abivax Sa  (NASDAQ: ABVX)
 
Price: $111.7300 $-1.62 -1.429%
Day's High: $114.33000183105469 Week Perf: -5.26 %
Day's Low: $ 111.36 30 Day Perf: -10.56 %
Volume (M): 1,056,533 52 Wk High: $ 148.83
Volume (M$): $ 0 52 Wk Avg: $113.42
Open: $112.17 52 Wk Low: $69.81



 Market Capitalization (Millions $) 7,768
 Shares Outstanding (Millions) 70
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -376
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company develops drug candidates utilizing proprietary or licensed technologies in collaboration with academic partners and pharmaceutical companies. It depends on partnerships and strategic alliances for the development, manufacturing, and commercialization of its drug candidates. The company faces competition from both larger and smaller firms and is subject to risks associated with regulatory approvals, pricing, insurance coverage, and reimbursement, which impact the market acceptance and profitability of its drugs.


   Company Address: 7-11 boulevard Haussmann Paris 75009
   Company Phone Number: 1 53 83 09 63   Stock Exchange / Ticker: NASDAQ ABVX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -0.7%    
EBS        17.76% 
OPK   -0.68%    
PFE        1.75% 
REGN   -3.55%    
SIGA        6.8% 
• View Complete Report
   



Clinical Study

Positive Interim Results of Obefazimod in Long-Term Management of Moderate to Severe Ulcerative Colitis A Two-Year ...

Published Thu, Oct 3 2024 6:31 AM UTC

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by inflammation of the colon, resulting in a range of distressing symptoms. Current treatment options include aminosalicylates, corticosteroids, immunomodulators, and biologics; however, there remains a need for novel therapeutic agents that can effectively manage moderate to severe forms of the di...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 15.24
PEG (TTM) -

Financial Strength Current
Quick Ratio 8.2
Working Capital Ratio 8.75
Leverage Ratio (MRQ) 0.14
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.69 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 8.32 $
Book Value 7.33 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -34,221,295
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.